Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16255639 | 0.85 | KCNH2 (0.54) | KCNH2HRH3OPRM1SLC18A3PRCP | |
| SCHEMBL27498941 | 0.81 | KCNH2 (0.60) | KCNH2HRH3OPRM1SLC18A3PRCP | |
| SCHEMBL12158639 | 0.81 | KCNH2 (0.53) | KCNH2HRH3OPRM1SLC18A3PRCP | |
| SCHEMBL888843 | 0.81 | KCNH2 (0.53) | KCNH2HRH3OPRM1SLC18A3PRCP | |
| SCHEMBL24291907 | 0.79 | KCNH2 (0.53) | KCNH2HRH3OPRM1SLC18A3SIGMAR1 | |
| SCHEMBL10122844 | 0.76 | KCNH2 (0.48) | KCNH2HRH3OPRM1PRCP | |
| SCHEMBL10122846 | 0.76 | KCNH2 (0.48) | KCNH2HRH3OPRM1PRCP | |
| SCHEMBL2661616 | 0.76 | KCNH2 (0.56) | KCNH2HRH3OPRM1SLC18A3SIGMAR1 | |
| SCHEMBL15045186 | 0.76 | KCNH2 (0.61) | KCNH2HRH3PRCPLIPECA12 | |
| SCHEMBL2603282 | 0.76 | HRH3 (0.69) | KCNH2HRH3OPRM1SLC18A3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNH2 3278/4885HRH3 3208/4885OPRM1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.